170 related articles for article (PubMed ID: 22421142)
21. Structural proteins of Kaposi's sarcoma-associated herpesvirus antagonize p53-mediated apoptosis.
Chudasama P; Konrad A; Jochmann R; Lausen B; Holz P; Naschberger E; Neipel F; Britzen-Laurent N; Stürzl M
Oncogene; 2015 Jan; 34(5):639-49. PubMed ID: 24469037
[TBL] [Abstract][Full Text] [Related]
22. Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells.
Ye FC; Zhou FC; Nithianantham S; Chandran B; Yu XL; Weinberg A; Gao SJ
J Virol; 2013 Jun; 87(11):6326-35. PubMed ID: 23536671
[TBL] [Abstract][Full Text] [Related]
23. p53 inhibition by the LANA protein of KSHV protects against cell death.
Friborg J; Kong W; Hottiger MO; Nabel GJ
Nature; 1999 Dec 23-30; 402(6764):889-94. PubMed ID: 10622254
[TBL] [Abstract][Full Text] [Related]
24. Kaposi's Sarcoma-Associated Herpesvirus Infection Induces the Expression of Neuroendocrine Genes in Endothelial Cells.
Valiya Veettil M; Krishna G; Roy A; Ghosh A; Dutta D; Kumar B; Chakraborty S; Anju TR; Sharma-Walia N; Chandran B
J Virol; 2020 Mar; 94(8):. PubMed ID: 31969437
[TBL] [Abstract][Full Text] [Related]
25. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
26. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
27. FoxO1 Suppresses Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication and Controls Viral Latency.
Gao R; Li T; Tan B; Ramos da Silva S; Jung JU; Feng P; Gao SJ
J Virol; 2019 Feb; 93(3):. PubMed ID: 30404794
[TBL] [Abstract][Full Text] [Related]
28. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
29. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
30. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
[TBL] [Abstract][Full Text] [Related]
31. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
[TBL] [Abstract][Full Text] [Related]
32. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
33. Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells.
Santag S; Jäger W; Karsten CB; Kati S; Pietrek M; Steinemann D; Sarek G; Ojala PM; Schulz TF
Oncogene; 2013 Aug; 32(32):3676-85. PubMed ID: 22964633
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
35. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation.
Lu J; Verma SC; Murakami M; Cai Q; Kumar P; Xiao B; Robertson ES
J Virol; 2009 Jul; 83(14):7129-41. PubMed ID: 19439469
[TBL] [Abstract][Full Text] [Related]
36. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
37. Kaposi's sarcoma-associated herpesvirus infection promotes differentiation and polarization of monocytes into tumor-associated macrophages.
Bhaskaran N; Ghosh SK; Yu X; Qin S; Weinberg A; Pandiyan P; Ye F
Cell Cycle; 2017; 16(17):1611-1621. PubMed ID: 28750175
[TBL] [Abstract][Full Text] [Related]
38. Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.
Tso FY; West JT; Wood C
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651362
[TBL] [Abstract][Full Text] [Related]
39. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.
Schneider LS; Ulrich M; Lehr T; Menche D; Müller R; von Schwarzenberg K
Mol Oncol; 2016 Aug; 10(7):1054-62. PubMed ID: 27157929
[TBL] [Abstract][Full Text] [Related]
40. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
